AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
173.53
-1.30 (-0.74%)
At close: 1:02PM EST
Stock chart is not supported by your current browser
Previous Close174.83
Open175.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range173.11 - 175.43
52 Week Range169.61 - 256.80
Volume797,698
Avg. Volume3,564,157
Market Cap57.713B
Beta1.19
PE Ratio (TTM)5.29
EPS (TTM)32.82
Earnings DateFeb 6, 2018 - Feb 12, 2018
Forward Dividend & Yield2.80 (1.60%)
Ex-Dividend Date2017-11-16
1y Target Est230.89
Trade prices are not sourced from all markets
  • Merck's drug bust: 3 trades
    CNBC Videos4 days ago

    Merck's drug bust: 3 trades

    The Fast Money traders discuss Merck tumbling 2 percent today and hovering near bear market territory.

  • An Undervalued, Wide-Moat Name in Healthcare
    Morningstar10 days ago

    An Undervalued, Wide-Moat Name in Healthcare

    We think generic competition on Restasis is manageable and that Allergan has an innovative pipeline and strong aesthetics business.

  • Teva (TEVA) Stock Rises 5% on Reports of Massive Job Cuts
    Zacks11 hours ago

    Teva (TEVA) Stock Rises 5% on Reports of Massive Job Cuts

    Per an Israeli news release, Teva (TEVA) is expected to lay off 4000 employees

  • Market Realist2 days ago

    Teva on the Street: Analyst Recommendations in November 2017

    Teva is actively making progress toward divestiture opportunities. In November 2017, it divested Paragard to Cooper Surgical for $1.1 billion.

  • Top 10 Largest Pharmaceutical Companies By Revenue in 2017
    Insider Monkey2 days ago

    Top 10 Largest Pharmaceutical Companies By Revenue in 2017

    The top 10 largest pharmaceutical companies by revenue in 2017 are leading companies that have a large geographical presence, loyal customer base and technologically advanced manufacturing and R&D facilities. Though their businesses are recession-proof, a huge portion of their expenses has to be allocated to research and development to stay ahead of the competition. Medicine has […]

  • PR Newswire2 days ago

    Allergan to Present at the 2017 Citi Global Healthcare Conference

    DUBLIN, Nov. 22, 2017 /PRNewswire/ -- Allergan plc (AGN), a leading global biopharmaceutical company, today announced that Chief Commercial Officer William Meury will present at the 2017 Citi Global Healthcare Conference in New York City. The presentation will be webcast live and can be accessed on Allergan's Investor Relations website at www.allergan.com/investors. Allergan plc (AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

  • Investopedia5 days ago

    Top Stocks Billionaire David Tepper Bought and Sold in Q3: 13F Filing

    Tepper's Appaloosa Management is up 5.6% over last quarter, according to a 13F filing.

  • PR Newswire9 days ago

    Allergan to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference

    DUBLIN, Nov. 16, 2017 /PRNewswire/ -- Allergan plc (AGN), a leading global biopharmaceutical company, today announced that David Nicholson, Allergan's Chief Research and Development Officer, and Armin Szegedi, Allergan's Vice President of Clinical Development/CNS, will present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference in Boston, Massachusetts. The presentation will be webcast live and can be accessed on Allergan's Investor Relations website at www.allergan.com/investors. Allergan plc (AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

  • Market Realist10 days ago

    Inside Novartis’s Ophthalmology Drugs Now

    In 3Q17, Novartis's (NVS) Lucentis generated revenues of ~$481 million, which was ~5% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).

  • Allergan's Vraylar Gets FDA Nod for Maintenance Therapy
    Zacks10 days ago

    Allergan's Vraylar Gets FDA Nod for Maintenance Therapy

    Allergan's (AGN) schizophrenia capsule, Vraylar, secures an FDA approval for its label expansion as a maintenance treatment option in the market.

  • Motley Fool10 days ago

    Here's What's Behind Synergy Pharmaceuticals' 15.6% Drop Today

    The company's making inroads with its first commercial-stage drug, but expenses could present big headwinds.

  • PR Newswire11 days ago

    Overactive Bladder Causes Significant Burden, Regardless of Age Amongst Adults

    DUBLIN and CHARLESTON, S.C., Nov. 14, 2017 /PRNewswire/ -- Allergan, Inc. (AGN), in partnership with the National Association For Continence (NAFC), today announced the results of a new survey that revealed the impact of overactive bladder (OAB) and related symptoms on those living with the condition, as well as the extremes to which people will go to cope with or hide their symptoms. "People can start experiencing symptoms of OAB at an early age, learning to settle for a lifetime of silently struggling with an uncomfortable condition," says Steven Gregg, PhD, Executive Director of the NAFC. The survey found that 86 percent of respondents experience OAB symptoms multiple times a day.

  • Reuters11 days ago

    Allergan to sell a quarter of its Teva stake in first quarter 2018

    Allergan Plc said on Monday it will sell just under a quarter of its roughly 10 percent stake in Israel's Teva Pharmaceutical Industries during the first quarter of 2018, as it starts to unwind its position in the struggling generic drugmaker. Botox maker Allergan said in a filing with the Securities and Exchange Commission that it will sell 25 million shares to a JP Morgan Chase and Co unit - acting as a dealer for the shares - sometime next quarter. The JP Morgan unit will pay a price based on the average trading price over a yet-to-be determined period before the sale.

  • Amgen Gets Positive CHMP Opinion to Expand Nplate's Label
    Zacks12 days ago

    Amgen Gets Positive CHMP Opinion to Expand Nplate's Label

    Amgen (AMGN) received positive CHMP opinion to expand Nplate's label to include pediatric patients and also for the marketing application of Avastin biosimilar.

  • MarketWatch12 days ago

    Allergan wins FDA approval for use of Vraylar in maintenance treatment of schizophrenia

    Allergan plc said Monday it has won U.S. Food and Drug Administration approval for use of Vraylar in the maintenance treatment of schizophrenia. The FDA approved the company's supplemental new drug application ...

  • PR Newswire12 days ago

    Allergan Receives FDA Approval For Use of VRAYLAR™ (cariprazine) in the Maintenance Treatment of Schizophrenia

    -- Label Expansion Includes New Data Showing Long-Term VRAYLAR Therapy Delayed Time to Relapse Compared to Placebo Over the Course of up to 72 Weeks -- DUBLIN , Nov. 13, 2017 /PRNewswire/ -- Allergan plc ...

  • PR Newswire15 days ago

    Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer

    THOUSAND OAKS, Calif., Nov. 10, 2017 /PRNewswire/ -- Amgen (AMGN) and Allergan plc. (AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of ABP 215, a biosimilar to Avastin® (bevacizumab).

  • Aerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus
    Zacks16 days ago

    Aerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus

    Increased operating expenses mar Aerie's (AERI) Q3 performance.

  • PR Newswire17 days ago

    Allergan to Present Dynamic Eye Care Data at American Academy of Ophthalmology Meeting in New Orleans

    DUBLIN , Nov. 8, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced its data will be presented at the annual American Academy of Ophthalmology (AAO) ...

  • Why Neos Therapeutics Inc Rose 13.7% In October
    Motley Fool17 days ago

    Why Neos Therapeutics Inc Rose 13.7% In October

    The game of cat and mouse continues.

  • U.S. senators press Allergan for details on patent deal with tribe
    Reuters17 days ago

    U.S. senators press Allergan for details on patent deal with tribe

    Democratic Senators Sherrod Brown, Maggie Hassan, Amy Klobuchar, Al Franken and Patty Murray made the request for documents in a letter to Allergan Chief Executive Brent Saunders. Allergan contends the tribe’s status as a sovereign entity places the patents outside the jurisdiction of the U.S. Patent Trial and Appeal Board, or PTAB.

  • Senators question Allergan CEO on tribe patent deal
    CNBC17 days ago

    Senators question Allergan CEO on tribe patent deal

    A group of five senators said the deal was a "blatant attempt to further Allergan's market monopoly" on its $1.5 billion eye drug, Restasis.

  • TheStreet.com18 days ago

    Teva's Stock Could Crash Another 50% After Debt Cut to Junk

    Fitch cut Teva's credit rating by two levels, down to junk grade. HSBC analysts say shares could drop another 50% to $6.

  • Allergan Keeps Heading Lower. Is It Time to Buy?
    Motley Fool18 days ago

    Allergan Keeps Heading Lower. Is It Time to Buy?

    Allergan's stock slips for the third straight month in October.